FINWIRES · TerminalLIVE
FINWIRES

Element Solutions Offers Attractive Risk-Reward Amid Strong Electronics Demand, UBS Says

By

Element Solutions' (ESI) strong electronics demand and improving growth profile create an attractive risk-reward setup for the stock, UBS Securities said.

The brokerage said in a Thursday note that the stock started to re-rate through H1, supported by catalysts like two higher growth acquisitions around electronics and the divestment of slower growth graphics.

The company's earnings setup for 2026 is beatable, and the 2027 consensus could be conservative if robust electronics trends continue, according to the note.

The company's risk/reward skew is attractive at current levels, analysts wrote, adding that they expect adjusted EPS compound annual growth rate of around 17%.

UBS reiterated its buy rating on the stock and adjusted its price target to $47 per share from $49.

Price: $33.28, Change: $+0.12, Percent Change: +0.36%

What else is happening in Wire?

Wire

Loop Industries to Evaluate Alternatives, India Joint Venture Financing

Loop Industries (LOOP) formed a committee to evaluate alternatives aimed at advancing commercialization and strengthening its capital position, including a broader project-financing structure for its planned India joint venture.The review will consider "strategic investments, project-level financing, licensing and commercial partnerships, regional joint ventures, business combinations, corporate-structure alternatives, a potential sale, merger or going-private transaction," the company said Thursday in a statement.Loop said there is no assurance the process will result in a sale, merger, going-private transaction or any other transaction or outcome.The review follows Jeff Geygan's appointment as chairman and the separation of the chairman and CEO roles, establishing a board-led process to evaluate capital needs and strategy.Loop shares rose 2% in after-hours trading.

$LOOP
Wire

Top Cryptocurrencies Rise; Bitcoin Tops $76,000 Level

Major digital assets rose Thursday, with Bitcoin (BTC-USD) topping the $76,000 level.The CoinDesk Market Index, which tracks dozens of digital assets including Bitcoin, rose 2% in the past 24 hours. The Nasdaq 100 rose 1.8%, the S&P 500 added 1.2%, and the Dow Jones Industrial Average increased 0.6%.Bitcoin gained 0.8% to $76,473, according to CoinMarketCap data. The most popular cryptocurrency's 24-hour trading volume dropped 24.4% to $23.4 billion.Ethereum (ETH-USD), the second-largest digital asset by market value, rose 1.8% to $2,445.XRP (XRP-USD) declined 0.3%, BNB (BNB-USD) rose 1.6%, and Solana (SOL-USD) gained 2.6%. Dogecoin (DOGE-USD) increased 1.5%, while Cardano (ADA-USD) advanced 3.7%.The total market value of the cryptocurrency industry rose 1.2% in the past 24 hours to $2.62 trillion, with trading volume dropping 12.6% to $77 billion.Price: $76600.00, Change: $+456.19, Percent Change: +0.60%

$ADA-USD$BNB-USD$BTC-USD$DOGE-USD$ETH-USD$SOL-USD$XRP-USD
Wire

Ultragenyx Shares Rise After FDA Approval for Sanfilippo Syndrome Treatment

Ultragenyx Pharmaceutical (RARE) shares rose 11% after the company won FDA approval for Fayuvi, the first treatment for children with Sanfilippo syndrome type A, a rare genetic condition that progressively damages the brain and nervous system.Delivered as a one-time IV infusion, Fayuvi uses a modified virus to deliver a healthy gene, replacing the enzyme the patients lack. the FDA said Thursday in a statement. In clinical trials, treated children aged 2 to 5 maintained or improved their cognitive abilities compared to historical patient outcomes, the agency said.The FDA noted common side effects like fever, nausea, and elevated liver enzymes. The label also warns of potential long-term risks, including blood clotting issues and tumor formation, requiring patients to take immune-suppressing steroids around the time of treatment.Price: $14.34, Change: $+1.46, Percent Change: +11.34%

$RARE